http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
석기태,김현수,김문영,김재우,어영,장인호,김수기,최응호,김명조,주정수,백순구 대한의학회 2010 Journal of Korean medical science Vol.25 No.3
Eradication regimens for Helicobacter pylori infection have some side effects, compliance problems, relapses, and antibiotic resistance. Therefore, alternative anti-H. pylori or supportive antimicrobial agents with fewer disadvantages are necessary for the treatment of H. pylori. We investigated the pH-(5.0, 6.0, 7.0, 8.0, 9.0, and 10.0)and concentration (0.032, 0.064, 0.128, 0.256, 0.514, and 1.024 mg/mL)-dependent antibacterial activity of crude urushiol extract from the sap of the Korean lacquer tree (Rhus vernicifera Stokes) against 3 strains (NCTC11637, 69, and 219)of H. pylori by the agar dilution method. In addition, the serial (before incubation, 3,6, and 10 min after incubation) morphological effects of urushiol on H. pylori were examined by electron microscopy. All strains survived only within pH 6.0-9.0. The minimal inhibitory concentrations of the extract against strains ranged from 0.064mg/mL to 0.256 mg/mL. Urushiol caused mainly separation of the membrane, vacuolization,and lysis of H. pylori. Interestingly, these changes were observed within 10 min following incubation with the 1×minimal inhibitory concentrations of urushiol. The results of this work suggest that urushiol has potential as a rapid therapeutic against H. pylori infection by disrupting the bacterial cell membrane.
석기태,김현수,Chang Seob Lee,Il Young Lee,김문영,김재우,백순구,권상옥,이동기,함영림 대한소화기내시경학회 2011 Clinical Endoscopy Vol.44 No.2
Background/Aims: Rebleeding after endoscopic therapy for non-variceal upper gastrointestinal hemorrhage (NGIH) is the most important predictive factor of mortality. We evaluated the risk factors of rebleeding in patients undergoing endoscopic therapy for the NGIH. Methods: Between January 2003 and January 2007, 554 bleeding events in 487 patients who underwent endoscopic therapy for NGIH were retrospectively enrolled. We reviewed the clinicoendoscopical characteristics of patients with rebleeding and compared them with those of patients without rebleeding. Results: The incidence of rebleeding was 21.7% (n=120). In the multivariate analysis, initial hemoglobin level ≤9 g/dL (p=0.002; odds ratio [OR], 2.433), inexperienced endoscopist with less than 2 years of experience in therapeutic endoscopy (p=0.001; OR, 2.418), the need for more 15 cc of epinephrine (p=0.001; OR, 2.570), injection therapy compared to thermal and injection therapy (p=0.001; OR, 2.840), and comorbidity with chronic renal disease (p=0.004; OR, 2.908) or liver cirrhosis (p=0.010; OR, 2.870) were risk factors for rebleeding following endoscopic therapy. Conclusions: Together with patients with low hemoglobin level at presentation, chronic renal disease, liver cirrhosis, the need for more 15 cc of epinephrine, or therapy done by inexperienced endoscopist were risk factors for the development of rebleeding.
진행성 대장 선종에서 S상결장내시경과 2회 면역화학 대변잠혈반응검사의 진단 민감도
석기태,김현수,김정권,김정민,지명관,지상원,백순구,이동기,권상옥 대한소화기내시경학회 2004 Clinical Endoscopy Vol.28 No.6
Background/Aims: Because detection and removal of colonic adenoma provided an opportunity to prevent colorectal cancer, advanced adenoma (>10 mm, villous or high grade dysplasia) should be the major target of screening. In this study, we assessed the diagnostic sensitivity of one- or two-time immunochemical fecal occult blood test (i-FOBT), flexible sigmoidoscopy and their combination in patients with advanced adenoma or non-advanced adenoma. Methods: From January to October 2002, we performed colonoscopy with i-FOBT using latex agglutination method in 879 individuals. Among these, we diagnosed 234 polyps in 93 patients with advanced adenoma and 179 polyps in 109 patients with non-advanced adenoma. After the diagnosis of adenoma, second i-FOBT was done before polypectomy. Based on these data, we evaluated the diagnostic sensitivities of i-FOBT, flexible sigmoidoscopy and their combination for patients with advanced adenoma or non-advanced adenoma. Results: The diagnostic sensitivity of one- or two-time i-FOBT, flexible sigmoidoscopy and flexible sigmoidoscopy with two-time i-FOBT in patients with advanced adenoma vs.non-advanced adenoma were 17.2% vs. 18.3%, 28.0% vs. 29.4%, 70.1% vs. 66.1% and 81.7% vs. 78.0%. Although repeated application of i-FOBT enhanced diagnostic sensitivity for colon adenoma, this test or combination with flexible sigmoidoscopy did not differentiate advanced adenoma from non-advanced adenoma. Conclusions: Although it fails to detect one fifth of colon adenoma, combined two-time i-FOBT testing with flexible sigmoidoscopy is an effective and feasible screening modality for advanced colon adenoma. 목적: 대장암의 전암 병변인 선종을 조기에 발견하여 제거하는 대장암의 이차적 예방은 매우 중요하며, 특히 비진행성 선종보다는 진행성 선종이 선별검사의 목표가 된다. 저자 등은 진행성 선종으로 진단된 환자에서 S상결장내시경검사, 2회의 면역화학 대변잠혈반응검사(Immunochemical Fecal Occult-Blood Testing, i-FOBT) 각각과 조합의 진단 민감도를 알아보고 선별검사로서의 유용성을 알아보고자 하였다. 대상 및 방법: 2002년 1월부터 10월까지 원주의과대학 원주기독병원에서 대장내시경검사 전 라텍스 응집법을 이용한 i-FOBT를 시행한 879명 중 진행성 선종으로 진단받은 93명(234개의 선종)과 비진행성 선종으로 진단받은 109명(179개의 선종)을 대상으로 하였다. 대장 선종의 진단 최소 7일 후에 입원하여 용종제거술 전에 두 번째 i-FOBT를 시행하였다. S상결장내시경검사는 대장내시경검사에서 하행 결장까지의 관찰결과를 토대로 용종의 발견여부를 판정하였으며 각 군에서 각각 1회, 2회 i-FOBT, S상결장내시경검사, 그리고 이들 조합검사의 진단 민감도를 알아보았다. 결과: 진행성 선종군/비진행성 선종군에서 1회 및 2회의 i-FOBT의 진단 민감도는 각각 17.2%/18.3%, 28.0%/29.4%로 i-FOBT의 검사의 반복은 선종의 진단 민감도를 높였다. S상결장내시경검사 단독 그리고 S상결장내시경검사와 2회의 i-FOBT를 조합한 경우 대장 진행성/비진행성 선종군의 진단 민감도는 70.1%/66.1%에서 81.7%/78.0%로 증가하지만 양 군 사이의 진단 민감도 차이는 없었다. 결론: 대장암의 전구 병소인 진행성 선종의 선별검사로서 S상결장내시경검사와 2회 i-FOBT의 조합은 진단 민감도가 높아 유용한 선별검사법으로 판단되며 향후 국내 실정에 맞는 대장 선종-암의 명확한 선별검사법을 제시하기 위하여 대장내시경검사와 비용-효과 및 대장암의 생존율을 고려한 대규모의 전향적인 연구가 필요하다.
석기태 대한간학회 2013 간학회 싱글토픽 심포지움 Vol.2013 No.2
Portal hypertension is a severe, almost unavoidable complication of chronic liver diseases and is responsible for the main clinical consequences of cirrhosis. Measurement of the hepatic venous pressure gradient (HVPG) is currently the best available method to evaluate the presence and severity of portal hypertension. Clinically significant portal hypertension is defined as an increase in HVPG to > or=10 mmHg; above this threshold, the complications of portal hypertension might begin to appear. Measurement of HVPG is increasingly used in clinical hepatology, and numerous studies have demonstrated that the parameter is a robust surrogate marker for hard clinical end points. The main clinical applications for HVPG include diagnosis, risk stratification, identification of patients with hepatocellular carcinoma who are candidates for liver resection, monitoring of the efficacy of medical treatment, and assessment of progression of portal hypertension. Patients who experience a reduction in HVPG of >or=20% or to <12 mmHg in response to drug therapy are defined as ``responders``. Responders have a markedly decreased risk of bleeding (or rebleeding), ascites, and spontaneous bacterial peritonitis, which results in improved survival. This review provides practical view points to ensure that the technique is performed properly.